Cendakimab (RPC4046, CC-93538), a humanized IgG1k monoclonal antibody targeting IL-13, leads to reductions in histological inflammation and endoscopic findings in EoE subjects by inhibiting the interaction of IL-13 with the matching IL-13Rα1 and IL-13Rα2 receptors, demonstrating potential efficacy in a multicenter trial (HEROES) of adult subjects with active EoE. Here, IL13 is linked to eosinophilic esophagitis.